trending Market Intelligence /marketintelligence/en/news-insights/trending/Ae1ISRFOtEDCHRkJ4JoMIQ2 content esgSubNav
In This List

Corporate Venture, Pluristem to advance limb treatment in Japan

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Corporate Venture, Pluristem to advance limb treatment in Japan

Pluristem Therapeutics Inc. is establishing a new joint venture company with Corporate Venture Capital Ltd. to develop and commercialize its PLX-PAD cell therapy in Japan.

The parties have signed a binding term sheet and expect to reach a definitive agreement by March 31, 2017, under which Corporate Venture's investment fund Sosei RMF1 will invest $11 million for a 65% stake.

Corporate Venture itself is part of the Sosei Group Corp.

PLX-PAD is currently being developed for the treatment of critical limb ischemia, a severe obstruction of arteries that leads to severe pain and skin ulcers or sores on hands, feet and legs.

The treatment has been approved for clinical trial in Japan.